C4 Therapeutics (CCCC) to Release Quarterly Earnings on Thursday

Key Points

• C4 Therapeutics is set to announce its Q2 2025 earnings on August 7th, with analysts expecting losses of ($0.41) per share and revenue of $5.24 million.
• The company reported a negative return on equity of 45.86% and a negative net margin of 259.60% in its last quarterly earnings.
• Institutional investors hold 78.81% of C4 Therapeutics' stock, with AQR Capital Management increasing its stake by 957.6% in the first quarter.

C4 Therapeutics (NASDAQ:CCCC - Get Free Report) is expected to be announcing its Q2 2025 earnings results before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.41) per share and revenue of $5.24 million for the quarter.

C4 Therapeutics (NASDAQ:CCCC - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported ($0.37) EPS for the quarter, topping analysts' consensus estimates of ($0.48) by $0.11. The firm had revenue of $7.20 million during the quarter, compared to analyst estimates of $3.54 million. C4 Therapeutics had a negative net margin of 259.60% and a negative return on equity of 45.86%. On average, analysts expect C4 Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

C4 Therapeutics Price Performance

Shares of C4 Therapeutics stock traded up $0.07 during trading on Friday, hitting $2.12. 750,601 shares of the company were exchanged, compared to its average volume of 1,529,366. The firm's fifty day moving average price is $1.73 and its 200 day moving average price is $2.09. C4 Therapeutics has a 1-year low of $1.09 and a 1-year high of $7.22.

Hedge Funds Weigh In On C4 Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. AQR Capital Management LLC increased its stake in C4 Therapeutics by 957.6% during the 1st quarter. AQR Capital Management LLC now owns 140,532 shares of the company's stock worth $225,000 after purchasing an additional 127,244 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of C4 Therapeutics by 8.6% in the first quarter. Goldman Sachs Group Inc. now owns 622,720 shares of the company's stock valued at $996,000 after buying an additional 49,065 shares during the period. Finally, Acadian Asset Management LLC bought a new stake in shares of C4 Therapeutics during the first quarter worth $43,000. 78.81% of the stock is owned by institutional investors.

About C4 Therapeutics

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.